Free Trial
NYSE:RMD

ResMed Q4 2025 Earnings Report

ResMed logo
$257.64 +1.22 (+0.48%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$257.50 -0.14 (-0.05%)
As of 07/18/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed EPS Results

Actual EPS
N/A
Consensus EPS
$2.47
Beat/Miss
N/A
One Year Ago EPS
N/A

ResMed Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.33 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

ResMed Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

ResMed Earnings Headlines

Zacks Research Has Positive Estimate for ResMed Q1 Earnings
Royal Bank Of Canada Upgrades ResMed (NYSE:RMD) to Outperform
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
1RMD : Analyst Expectations For ResMed's Future
See More ResMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ResMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ResMed and other key companies, straight to your email.

About ResMed

ResMed (NYSE:RMD), founded in 1989 by engineer Peter C. Farrell, is a global leader in the development and manufacture of medical devices and cloud-connected software applications for the diagnosis, treatment and management of respiratory disorders. Headquartered in San Diego, California, the company pioneered the use of continuous positive airway pressure (CPAP) therapy for sleep apnea and has since expanded its product portfolio to address a broad range of breathing-related conditions.

The company’s core product offerings include advanced CPAP and bilevel devices, mask systems and ventilators designed for both home and hospital settings. ResMed continuously invests in research and development to enhance device comfort, efficacy and connectivity, integrating sensors and algorithms that allow for real-time monitoring of patient compliance and therapy outcomes. Its ventilator line supports critical care and noninvasive ventilation, catering to patients with chronic obstructive pulmonary disease (COPD), neuromuscular and other respiratory conditions.

Operating in more than 140 countries, ResMed serves a diverse customer base spanning sleep clinics, home healthcare providers and hospitals. The company has strengthened its position in digital health through its cloud platform, which aggregates patient data for care teams and enables remote monitoring and telehealth services. This digital ecosystem fosters greater patient engagement, streamlines clinician workflows and supports value-based care models in both mature and emerging markets.

Under the leadership of CEO Mick Farrell, who succeeded the founder in 2013, ResMed has focused on innovation, strategic acquisitions and global expansion. The executive team includes seasoned professionals in engineering, clinical affairs and global distribution, reflecting the company’s commitment to advancing respiratory care. As the prevalence of sleep apnea and chronic respiratory diseases continues to rise, ResMed aims to leverage its technology and data analytics capabilities to improve patient outcomes and reduce healthcare costs worldwide.

View ResMed Profile

More Earnings Resources from MarketBeat